AsiaNet 89054

PHILADELPHIA, April 28, 2021 /PRNewswire=KYODO JBN/ --

ERT (

https://c212.net/c/link/?t=0&l=en&o=3132623-1&h=2992466112&u=https%3A%2F%2Fwww.ert.com%2F&a=ERT

), a global leader in clinical endpoint data solutions, today announced the

close of its merger with Bioclinica (

https://c212.net/c/link/?t=0&l=en&o=3132623-1&h=2577688697&u=https%3A%2F%2Fwww.bioclinica.com%2F&a=Bioclinica

), a technological and scientific leader in clinical imaging. This combination

creates the global leader in clinical trial endpoint technology and leading

partner to pharmaceutical and biotechnology companies, providing best-in-class

technology, scientific and therapeutic expertise, and digital innovation with

an unrelenting focus on customer service.

Logo - https://mma.prnewswire.com/media/1490004/ERT_Logo.jpg

Logo - https://mma.prnewswire.com/media/1490003/Bioclinica_Logo.jpg

The transaction combines Bioclinica's expertise in imaging, eClinical software

and drug safety solutions with ERT's expertise in eCOA, cardiac safety,

respiratory and wearables. By joining forces, ERT strengthens the most

comprehensive and robust endpoint data collection portfolio in the industry

with greater integrated and digital solutions across essential endpoints -

including imaging, respiratory, cardiac, eCOA with connected devices, as well

as precision motion.

Together, the combined company is committed to accelerating market-leading

investments in research and development to bring more integrated endpoint

technology, and provide access to a broader team of medical and scientific

industry leaders. This integrated approach will improve the clinical trial

experience for sites, customers, and patients.

"We are excited to welcome Bioclinica and look forward to delivering even

greater clinical trial success for our customers through our expanded

integrated offerings and innovation roadmap," said Joe Eazor, President and CEO

of ERT. "Together, as we plan our exciting future, our top priorities are

ensuring our current services continue without interruption or change, and to

listening closely to our customers to better serve their needs.

"Our newly combined organization delivers on our commitment to accelerate

innovation for today's complex and fast-moving clinical trials environment.

This will enable us to be more capable partners to our customers, and, more

importantly, enhance our ability to help improve health and save lives."

Joe Eazor is the CEO of the merged company, and the management team will be

composed of a combination of both ERT and Bioclinica executives.

Learn more about the integration of ERT and Bioclinica by visiting the

dedicated merger webpage (

https://c212.net/c/link/?t=0&l=en&o=3132623-1&h=367316166&u=https%3A%2F%2Fwww.ert.com%2Fbioclinica-merger%2F&a=dedicated+merger+webpage

).

About ERT

ERT (eResearch Technology) is a global data and technology company that

minimizes uncertainty and risk in clinical trials so that its customers can

move ahead with confidence. With nearly 50 years of clinical and therapeutic

experience, ERT balances knowledge of what works with a vision for what's next,

so it can adapt without compromising standards.

Powered by the company's EXPERT(R) technology platform, ERT's solutions enhance

trial oversight, enable site optimization, increase patient engagement and

measure the efficacy of new clinical treatments while ensuring patient safety.

In 2019, 75% of all FDA drug approvals came from ERT-supported studies. Pharma

companies, biotechs, and CROs have relied on ERT solutions across 16,000

studies, spanning more than five million patients to date. By identifying trial

risks before they become problems, ERT enables customers to bring clinical

treatments to patients quickly - and with confidence.

For more information, please visit ert.com (

https://c212.net/c/link/?t=0&l=en&o=3132623-1&h=3750397762&u=http%3A%2F%2Fwww.ert.com%2F&a=ert.com

) or follow us on LinkedIn (

https://www.linkedin.com/authwall?trk=gf&trkInfo=AQHD1_QMciJsjgAAAXjn5qoIQKW2eoaTcNEYg6dZmk5X4YMHNCMlC-V1d7JdVG0ieZ6iEO9g7gswb3Q7oCslez7vqAz6UcON1l1ROQWu6ynGveVpG7FFT20B8SNxM6AxmwVxz48=&originalReferer=&sessionRedirect=https%3A%2F%2Fwww.linkedin.com%2Fcompany%2Fert%2F

) and Twitter (

https://c212.net/c/link/?t=0&l=en&o=3132623-1&h=299416367&u=https%3A%2F%2Ftwitter.com%2FERTglobal&a=Twitter

).

ERT Media Contact

Terry Stanulis

Director, Public Relations and Thought Leadership

terry.stanulis@ert.com

+1 (862) 288-0329

SOURCE:  ERT